~~<i id='EA3A4E30CE'><strike id='EA3A4E30CE'><tt id='EA3A4E30CE'><pre id='EA3A4E30CE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：comprehensive 2025-10-02 01:07:56 - browse：8

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Amylyx ALS drug failure raises questions and concerns

leisure time

focus

leisure time

Wikipedia

explore

Anexamroominawomen'shealthcenterinIndiana,whereabortionsarenowbannedwithverylimitedexceptions.ScottO

WSS

Russian and Belarusian players banned from a women's tennis tournament in Prague

Snowpack in the West is melting rapidly. Where will all that extra water go?

Snowpack in the West is melting rapidly. Where will all that extra water go?

The problem with charging patients to message their doctors

House GOP plan to stem drug shortages differs from Democrats’

Change Healthcare payments predicted restored March 15

entertainment

leisure time

leisure time

Medicare details structure of new drug price negotiation program

Change Healthcare payments predicted restored March 15

Duchenne breakthrough therapy leaves behind pioneering families

Headspace, Meta partner to launch VR meditation app for Quest

Continuity nursing helped my family in our darkest PICU moments

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

State Dept. review finds Biden bears some blame for Afghanistan failures

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Medical leaders decry Supreme Court decision on affirmative action

Just how do doctors, lawmakers, and the public define abortion?

leisure time

Teacher posts viral 'school supply rant' with advice for parents

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

RSV shot was 90% effective at preventing hospitalizations in kids

Many immigrants are left out of maternal health programs

First medicine developed to treat MASH expected to be approved soon

First medicine developed to treat MASH expected to be approved soon

focus

leisure time

Wikipedia

explore